Galectin治疗 GALT 深 沪
已收盘 02-06 16:00:00 美东时间
2.80
-0.030
-1.06%
华盛通- 最 高2.89
- 今 开2.82
- 成交量 47.38万股
- 最 低 2.67
- 昨 收 2.83
- 总市值 1.81亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 1.12
- 委 比 41.52%
- 总股本 6447.28万
- 历史最高 19.11
- 量 比 1.83
- 振 幅 7.77%
- 历史最低 0.49
- 每 手 1
- 风险率 1.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers
Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers Galectin Therapeutics Inc. has approved cash retention bonuses for two of its top executives. Chief Medical Officer Dr. Khurram Jamil will receive a $300,000 bonus, while Chief Financial Officer Jack Callicutt wil
01-22 06:01
Galectin Advances Belapectin Program, Secures New Insider Financing
Galectin Therapeutics ( ($GALT) ) has issued an update. On December 19, 2025, G...
2025-12-19 21:14
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11
HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and raises the price target from $6 to $11.
2025-12-17 20:44
PureTech Health Announces Initial Topline Results From Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In Patients With r/r AML And High-Risk MDS
LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially
2025-12-06 02:02
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
Galectin Therapeutics ( ($GALT) ) just unveiled an announcement. On December 3,...
2025-12-04 01:28
Galectin Therapeutics GAAP EPS of -$0.13
Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.13. More on Galectin Therapeutics Galectin: With Time Ticking, A Partner Is Needed To Revitalize MASH Program Seeking Alpha’s Quant Ratin...
2025-11-14 21:10
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
The Phase 2 NAVIGATE trial demonstrates that belapectin 2 mg/kg consistently reduces liver stiffness, new variceal development, and improves biomarkers in patients with compensated MASH cirrhosis and portal hypertension, with significant antifibrotic and disease-modifying potential.
2025-11-10 13:00
PureTech Health To Share New Data From Ongoing Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In r/rAML At ASH 2025
LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy and in
2025-11-03 22:18
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Galectin Therapeutics, Inc. announced its participation in the H.C. Wainwright 9th Annual MASH Virtual Investor Conference on October 21, 2025. The company's management, including CEO Joel Lewis and CMO Khurram Jamil, will present and discuss their lead drug belapectin, a galectin-3 inhibitor targeting metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis. The presentation will be available via live and archived webcasts. Managem...
2025-10-20 12:00
